Pharmacist Chronic Kidney Disease On-Demand 1 credit hour

The EMPA-KIDNEY trial assessed the efficacy and safety of empagliflozin in patients with chronic kidney disease. This course discusses the results of the trial and its implication on your patients.

Learning Objectives

Upon successful completion of this application-based course, participants should be able to: 

1. Describe the pathophysiology and FDA-approved indications of empagliflozin.

2. Review the current treatment of chronic kidney disease.

3. Discuss the strengths, limitations, and results of the EMPA-KIDNEY trial.

4. Evaluate the role of empagliflozin for the progression of chronic kidney disease.

5. Apply clinical implications of the EMPA-KIDNEY study to a patient case.

Faculty

Catherine Gilmore, PharmD

Disclosures:

Dr. Gilmore has no relevant financial relationships with ineligible companies to disclose.

Course Details